ALRN 6924

Drug Profile

ALRN 6924

Alternative Names: ALRN6924

Latest Information Update: 28 Sep 2016

Price : $50

At a glance

  • Originator Aileron Therapeutics; Roche
  • Developer Aileron Therapeutics
  • Class Antineoplastics; Peptides
  • Mechanism of Action Proto-oncogene protein c mdm2 inhibitors; Tumour suppressor protein p53 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Haematological malignancies; Myelodysplastic syndromes; Solid tumours

Most Recent Events

  • 09 Sep 2016 Phase-I clinical trials in Acute myeloid leukaemia (Second-line therapy or greater) in USA (IV) (NCT02909972)
  • 09 Sep 2016 Phase-I clinical trials in Myelodysplastic syndromes (Second-line therapy or greater) in USA (IV) (NCT02909972)
  • 16 Nov 2013 Aileron Therapeutics acquires ALRN 6924 from Roche
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top